surpass-cvot tirzepatide Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized

26.75

★★★★☆4.8 (126)

In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx

21.21

★★★★★4.9 (98)

Original Article: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT)

20.83

★★★★★5.0 (157)

SURPASS-CVOT: Tirzepatide Significantly Reduces Major Kidney Events Compared to Dulaglutide in T2D

26.94

★★★★★4.7 (84)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

26.16

★★★★★4.9 (203)

SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes

24.10

★★★★★5.0 (176)

SURPASS-CVOT trial: Tirzepatide was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. #AHA25 View the slides here: https://t.co/6VQpBHFP2I

20.67

★★★★★4.8 (132)